Moderna noted the FDA did not identify any specific safety concerns with the vaccine and that the rejection was inconsistent ...

The US Food and Drug Administration has refused to accept an application from Moderna to review its first mRNA seasonal flu vaccine, the company said Tuesday, in another setback for the technology ...

For patients taking medications that don't work as expected or pharmaceutical companies struggling with clinical trial ...

The first study on deuterium-depleted water (DDW) concluded that a higher D/H ratio inside cells can trigger cell division.

Kailera will launch a global Phase 2 study of ribupatide this year, while Hengrui will push the asset into Phase 3 in China.

NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic ...

Their absence is a reminder that for children with cancer, time is never theoretical and the consequences of delay are irreversible. Each year, each month, and each day this bill stalled was another ...

Saeed bin Mubarak Al Hajeri, Minister of State and Chairman of the Board of Directors of the Emirates Drug Establishment, officially launched the Emirates Drug Establishment at the World Health Expo ...

Synthace, the leader in software and services for assay development, today announced a collaboration with Charles River Laboratories International, Inc. (Charles River), a leading global drug ...

SHELTON, CONNECTICUT / ACCESS Newswire / February 2, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a ...

The table below is a review of notable updates that occurred in January 2026 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.

Takeda Pharmaceutical will apply Iambic Therapeutics’ artificial intelligence (AI)-based technologies and wet lab capabilities to design and develop small molecule drugs through a multi-year tech and ...